NR4A1 and breast carcinoma: EPT use is largely viewed as a promotor, rather than initiator, of breast cancer, supported by both experimental54 and epidemiologic observations.55 These effects are likely predominantly receptor mediated, observed predominantly for hormone receptor–positive disease.